Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients
Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients
复制标题
DOI：
10.1016/s0926-9959(97)00146-3
复制
发表时间：
1998-01-01
影响因子：
9.2
通讯作者：
Murphy, GM
中科院分区：
文献类型：
--
作者：
Gibson, GE;O'Grady, A;Murphy, GM
背景肾移植受者皮肤癌的发病率增加，这可能是多个和aggressive.Objectives本研究的目的是检查化学预防作用的低剂量etretinate（0.3毫克/公斤/天）对皮肤癌的发展在肾移植recipients和监测维甲酸的毒性作用，在此dose.Methods所有的皮肤病变进行了计数和拍照治疗前etretinate。患者每月评估一次新的皮肤病变和Tor维甲酸toxicity.Results十一肾移植受者参加，有一个显着减少的皮肤癌的数量发生在etretinate治疗与治疗前相比，为3和6个月的治疗，并有减少皮肤癌的趋势，在12和18个月的治疗期间，不良反应耐受良好，无明显的生化影响observed.Conclusion小剂量etretinate是安全的，耐受性好，部分有效的化学预防皮肤癌的肾移植受者。(C)1998年Elsevier Science B.V.
Background Renal transplant recipients have an increased incidence of skin cancers, which may be multiple and aggressive.Objectives The purpose of this study was to examine the chemoprophylactic effects of low-dose etretinate (0.3 mg/kg/day) on skin cancer development in renal transplant recipients and to monitor retinoid toxic effects at this dose.Methods Ail skin lesions were counted and photographed prior to therapy with etretinate. Patients were assessed at monthly intervals for new skin lesions and Tor retinoid toxicity.Results Eleven renal transplant recipients participated, There was a significant reduction in the number of skin cancers which occurred during etretinate therapy compared with pre-treatment for 3 and 6 months of treatment, and a trend towards fewer skin cancers in the 12 and 18 month treatment periods, Side-effects were well-tolerated and no significant biochemical effects were observed.Conclusion Low dose etretinate is safe, well-tolerated and partially effective in chemoprophylaxis of skin cancer in renal transplant recipients. (C) 1998 Elsevier Science B.V.